Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has sold 9,265,312 shares of common stock of Arrowhead Pharmaceuticals, Inc. (“Arrowhead”) in a privately negotiated block trade. The Company expects to receive at least $174 million in gross proceeds from the block trade. In addition, Sarepta entered into an agreement with Arrowhead pursuant to which it will transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the Company’s previously announced $100 million milestone payment obligation.

“We are very pleased with the progress of our potentially best-in-class siRNA programs, including the advancement of our SRP-1003 program for DM1, triggering the $100 million milestone payment to our partner, Arrowhead,” said Doug Ingram, chief executive officer, Sarepta. “The sale of our equity investment is a strategic decision to help fund this milestone but does not change our conviction in the utility of the siRNA approach and our confidence in the work Arrowhead is doing to apply this technology across several disease states. We look forward to sharing early data from our FSHD and DM1 programs in the second half of this year.”

The Company’s $100 million milestone payment obligation was triggered following a review of the safety data and Arrowhead achieving the first of two predetermined enrollment targets, in the Phase 1/2 clinical study of SRP-1003, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Sarepta expects to release preliminary data from the Phase 1/2 study of SRP-1003 in the second half of 2025.